Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/26700
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWright, LM-
dc.contributor.authorDe Marco, M-
dc.contributor.authorVenneri, A-
dc.date.accessioned2023-06-20T16:15:02Z-
dc.date.available2023-06-20T16:15:02Z-
dc.date.issued2023-05-05-
dc.identifierORCID iD: Matteo De Marco https://orcid.org/0000-0002-9240-8067; Annalena Venneri .https://orcid.org/0000-0002-9488-2301.-
dc.identifier.citationWright, L.M., De Marco, M. and Venneri A. (2023). 'Current Understanding of Verbal Fluency in Alzheimer’s Disease: Evidence to Date', Psychology Research and Behavior Management, 16, pp.1691 - 1705. doi: 10.2147/PRBM.S284645.en_US
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/26700-
dc.description.abstractCopyright © 2023 The Author(s). Since their development, verbal fluency tests (VFTs) have been used extensively throughout research and in clinical settings to assess a variety of cognitive functions in diverse populations. In Alzheimer’s disease (AD), these tasks have proven particularly valuable in identifying the earliest forms of cognitive decline in semantic processing and have been shown to relate specifically to brain regions associated with the initial stages of pathological change. In recent years, researchers have developed more nuanced techniques to evaluate verbal fluency performance, extracting a wide range of cognitive metrics from these simple neuropsychological tests. Such novel techniques allow for a more detailed exploration of the cognitive processes underlying successful task performance beyond the raw test score. The versatility of VFTs and the richness of data they may provide, in light of their low cost and speed of administration, therefore, highlight their potential value both in future research as outcome measures for clinical trials and in a clinical setting as a screening measure for early detection of neurodegenerative diseases.en_US
dc.description.sponsorshipMDM is supported by an Alzheimer’s Association Research Grant (23AARG-1030190). AV is supported by funding obtained under the National Recovery and Resilience Plan (NRRP), Mission 4 Component 2 Investment 1.3 - Call for tender No. 341 of 15/03/2022 of Italian Ministry of University and Research funded by the European Union – NextGenerationEU, Project code PE0000006, Concession Decree No. 1553 of 11/10/2022 adopted by the Italian Ministry of University and Research, CUP D93C22000930002, “A multiscale integrated approach to the study of the nervous system in health and disease” (MNESYS).disease” (MNESYS).en_US
dc.format.extent1691 - 1705-
dc.format.mediumElectronic-
dc.languageen-
dc.publisherDove Medical Pressen_US
dc.rightsCopyright © 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.-
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/-
dc.subjectFluencyen_US
dc.subjectAlzheimer’s diseaseen_US
dc.subjectADen_US
dc.subjectsemanticen_US
dc.subjectmild cognitive impairmenten_US
dc.subjectMCIen_US
dc.titleCurrent Understanding of Verbal Fluency in Alzheimer’s Disease: Evidence to Dateen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.2147/prbm.s284645-
dc.relation.isPartOfPsychology Research and Behavior Management-
pubs.publication-statusPublished online-
pubs.volume16-
dc.identifier.eissn1179-1578-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.674.65 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons